Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an update.
Prescient Therapeutics Limited has announced an extension of its Share Purchase Plan (SPP) deadline to July 25, 2025, following shareholder requests for more time to submit applications. The SPP offers shares at a 16.7% discount to the average market price, reflecting strong shareholder support and participation from eligible directors, potentially enhancing the company’s financial position and stakeholder engagement.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing targeted and personalized therapies for cancer. The company operates in the biotechnology industry and aims to provide innovative cancer treatment solutions.
Average Trading Volume: 1,036,168
Technical Sentiment Signal: Hold
Current Market Cap: A$37.85M
See more data about PTX stock on TipRanks’ Stock Analysis page.